Compare Johnson & Johnson (JNJ) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Invesco S&P 500 Low Volatility ETF — how do they compare? Johnson & Johnson trades at $258.29 (market cap $618.09B), while Invesco S&P 500 Low Volatility ETF trades at $72.05 (market cap $6.94B). The key difference: Johnson & Johnson is far larger — about 89.1× Invesco S&P 500 Low Volatility ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Invesco S&P 500 Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Invesco S&P 500 Low Volatility ETF for 123 Days on average.
| JNJ | SPLV | |
|---|---|---|
Market Cap | $618.09B | $6.94B |
Volume | 6,050,983 | 1,663,703 |
Sector | Health | — |
52-Week High | $278.43 | $77.97 |
52-Week Low | $186.00 | $70.30 |
Typical Hold Time | 129 Days | 123 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
SPLV trades at $71.99, up 1.08% with a bearish technical outlook from moving averages. The ETF's sector overweights in Utilities, Real Estate, and Financials have contributed to underperformance versus the S&P 500. Recent dividend payments of $0.14 provide income support, while technical indicators show mixed signals with neutral oscillators.
Outlook remains cautious due to sector headwinds and unappealing growth-adjusted valuation. The fund's low-volatility focus offers defensive positioning amid market uncertainty, though continued underperformance relative to broader market indexes presents near-term challenges for total return investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
